Day One

• Faster innovation and development by removing regulatory barriers and accelerating the approval process for innovative solutions through regulatory sandboxes
• Using Denmark as a pilot example to demonstrate how regulatory sandboxes can support industry-led innovation
• Scalable inspiration for further regions, showing how this approach could encourage faster approval, development, and innovation of new ingredients across markets

• Accurate and reliable anthropometric measurements are critical for conducting infant formula growth monitoring studies (GMS)
• Variability in measurement tools such as weight scales, length measuring mats, and measuring tapes, can impact data quality, comparability, and user experience
• Our study systematically evaluated the performance, reproducibility, and usability of three models of each device type using a standardized process representative of GMS

• Define what truly moves a submission forward globally by aligning on essential evidence requirements, shared regulatory pain points, and practical opportunities to avoid redundant studies while meeting expectations across regions
• Shape forward‑looking approval strategies by anticipating unspoken regulatory concerns, learning from stalled innovations, and leveraging smarter preclinical, mechanistic, and phased‑trial designs that reduce risk and accelerate progress
• Strengthen cross‑industry collaboration for long‑term resilience with open dialogue between manufacturers and ingredient providers, identifying adaptable solutions, translating efficacy into credible claims, and preparing for the evolving oversight landscape driven by emerging government initiatives
• Bring manufacturers, ingredient innovators, regulators, and clinicians together to forge a single, globally resonant pathway for advancing novel infant formula ingredients, uniting efficacy evidence, regulatory foresight, and cross‑industry collaboration into one strategic discussion

A fast-paced, face-to-face networking session designed to ensure you leave with a direct connection to every expert in the room. Meet infant formula manufacturers, ingredient innovators, food-tech platforms, and researchers in a structured format that makes exchanging business cards effortless, so conversations on science, regulatory strategy, and commercialization can continue long after the event.

• Explore how naturally occurring milk-derived bioactives can be integrated into infant formula by leveraging the intrinsic composition of dairy ingredients
• Examine the production and integration of functional oligosaccharides, including galacto-oligosaccharides and sialylated structures, from lactose-rich whey permeate
• Review the integration of milk fat–derived lipid structures, including sn-2 palmitate–rich triglycerides and milk fat globule membrane components such as phospholipids and gangliosides
• Consider the recovery and application of immunoglobulins, immune-active proteins and selected low-molecular-weight milk constituents, including polyamines, from milk and dairy ingredient streams

• GOS naturally contains HMO like structures, offering functional similarities to human milk oligosaccharides
• Latest scientific insights on GOS: Advances in structural analysis and oligosaccharide characterization are enabling infant formula brands to increase oligosaccharide diversity
• Galactosyllactoses (GLs): A deeper look into GL structures found in GOS highlights their relevance in infant nutrition supporting gut health and immune development
• Next generation GOS: Emerging innovations will unlock additional oligosaccharide structures, further expanding the diversity available for infant formula
• Understanding the regulatory landscape to fully leverage the HMO like structures naturally present in GOS

• Highlighting how A2 protein and the naturally smaller structural quality of goat milk proteins support easier digestion, reducing the need for hydrolyzed formulas by aligning more closely with an infant’s digestive capacity
• Exploring why protein structure matters in infant formula, examining how softer curds and smaller protein forms in goat milk may help explain improved tolerance compared with conventional cow milk formulas
• Discussing emerging insights into sensitivity and allergy considerations, including real-world observations of symptom reduction in infants who struggle with cow milk proteins while clarifying where goat milk fits within the broader allergy conversation

• Reframe the limits of the traditional growth-studies by demonstrating why weight and length alone are insufficient to show ingredient value and how developmental biomarkers can reveal meaningful biological effects earlier
• Show how emerging microbiome, metabolic, immune, and neurodevelopmental measurements enable shorter, more informative studies that de-risk innovation
• Highlight next-generation study approaches including omics and AI that support precision nutrition claims without requiring long-term IQ or obesity outcomes
• Equip innovators with practical examples of non-growth endpoints that can demonstrate developmental benefit, support regulatory conversations, and expand the evidence toolkit for infant formula ingredients

• Meet evolving consumer demands by offering seed oil-free options, addressing a high concern for families
• Driving innovation in fat and lipid levels within formulas, ensuring optimal nutrition while exploring new ingredient profiles
• Provide parents with choices that make them feel good about what they’re feeding their babies, fostering trust and satisfaction

• Strain characterization: Comprehensive genomic and phenotypic analyses to confirm the identity, stability, and safety of the strain
• Toxicity studies and animal models: predictive tools for evaluating strain safety prior to human studies. What is needed for a probiotic strain?
• Clinical studies, is growth evaluation during intervention enough? While appropriate weight and length gain confirm that the strain does not negatively impact infant development, comprehensive safety validation also requires monitoring other outcomes as gastrointestinal tolerance, infection incidence, and any adverse events
• Experience with regulatory authorities across major regions, including the FDA, China, Europe, and Australia

• Translate clinical and mechanistic research into practical formula innovation, showing how OPN-enriched formulas can reduce infection rates, optimize calcium absorption, and support healthy gut microbiota, including Bifidobacteria and Lactobacilli populations
• Explore how OPN interacts with other bioactive ingredients, such as oligosaccharides and lipids, to amplify developmental outcomes, and provide guidance on realistic formulation approaches and near-term product opportunities
• Using advances in fermentation and biology to advance in new functional and nutritional directions without radical system change

• Exploring the connection between microbiome development, immune maturation, the exposome, and the role of early-life nutrition in shaping long-term health outcomes
• Reviewing how goatmilk-based infant formula can contribute a healthy microbiome
• Discussing possible future directions for optimizing the efficacy of microbiome targeted early-life nutrition in terms of functional microbial ensembles and key-taxa